Additional secondary abnormality, such as IKZF1 deletions, is found in about 84% of BCR-ABL1-positive B-ALL cases and is linked to chemotherapy resistance and a higher risk of relapse [111]. The gene discussed is IKZF1; the disease is acute lymphoblastic leukemia.